$24.71
-0.96[-3.74%]
At close: Apr 16
$24.71
0[0.00%]
After Hours: 4:00PM EDT
Surgery Partners
(NASDAQ:SGRY)Surgery Partners Stock (NASDAQ:SGRY), Analyst Ratings, Price Targets, Predictions
Surgery Partners Inc has a consensus price target of $46.93, established from looking at the 42 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Barclays, and Cantor Fitzgerald on April 10, 2024, March 6, 2024, and March 5, 2024. With an average price target of $40.33 between Cantor Fitzgerald, Barclays, and Cantor Fitzgerald, there's an implied 63.23% upside for Surgery Partners Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Barclays
RBC Capital
Citigroup
TD Cowen
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Surgery Partners
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | SGRY | Buy Now | Surgery Partners | $24.71 | 74.02% | Cantor Fitzgerald | Sarah James | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 03/06/2024 | SGRY | Buy Now | Surgery Partners | $24.71 | 41.64% | Barclays | Andrew Mok | → $35 | Initiates | → Equal-Weight | Get Alert |
| 03/05/2024 | SGRY | Buy Now | Surgery Partners | $24.71 | 74.02% | Cantor Fitzgerald | Sarah James | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | SGRY | Buy Now | Surgery Partners | $24.71 | 98.3% | RBC Capital | Ben Hendrix | → $49 | Reiterates | Outperform → Outperform | Get Alert |
| 02/27/2024 | SGRY | Buy Now | Surgery Partners | $24.71 | 69.97% | Citigroup | Jason Cassorla | $43 → $42 | Maintains | Buy | Get Alert |
| 02/27/2024 | SGRY | Buy Now | Surgery Partners | $24.71 | 74.02% | Cantor Fitzgerald | Sarah James | $43 → $43 | Maintains | Overweight | Get Alert |
| 11/14/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 41.64% | TD Cowen | Gary Taylor | $39 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/12/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 102.35% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 74.02% | Cantor Fitzgerald | Sarah James | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 102.35% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 106.39% | Barclays | Marc Solecitto | $56 → $51 | Maintains | Overweight | Get Alert |
| 07/31/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 102.35% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 102.35% | Mizuho | Ann Hynes | $48 → $50 | Maintains | Buy | Get Alert |
| 06/02/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 82.11% | B of A Securities | Kevin Fischbeck | $42 → $45 | Upgrade | Neutral → Buy | Get Alert |
| 05/12/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 94.25% | Mizuho | Ann Hynes | → $48 | Initiates | → Buy | Get Alert |
| 05/02/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 90.21% | RBC Capital | Ben Hendrix | → $47 | Reiterates | → Outperform | Get Alert |
| 05/02/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 102.35% | Benchmark | Bill Sutherland | → $50 | Reiterates | → Buy | Get Alert |
| 05/02/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 90.21% | Citigroup | Jason Cassorla | $40 → $47 | Maintains | Buy | Get Alert |
| 04/21/2023 | SGRY | Buy Now | Surgery Partners | $24.71 | 74.02% | Cantor Fitzgerald | Sarah James | → $43 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Surgery Partners (SGRY)?
The latest price target for Surgery Partners (NASDAQ: SGRY) was reported by Cantor Fitzgerald on April 10, 2024. The analyst firm set a price target for $43.00 expecting SGRY to rise to within 12 months (a possible 74.02% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Surgery Partners (SGRY)?
The latest analyst rating for Surgery Partners (NASDAQ: SGRY) was provided by Cantor Fitzgerald, and Surgery Partners reiterated their overweight rating.
When was the last upgrade for Surgery Partners (SGRY)?
The last upgrade for Surgery Partners Inc happened on November 14, 2023 when TD Cowen raised their price target to $35. TD Cowen previously had a market perform for Surgery Partners Inc.
When was the last downgrade for Surgery Partners (SGRY)?
The last downgrade for Surgery Partners Inc happened on June 15, 2022 when B of A Securities changed their price target from N/A to $36 for Surgery Partners Inc.
When is the next analyst rating going to be posted or updated for Surgery Partners (SGRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surgery Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surgery Partners was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Surgery Partners (SGRY) correct?
While ratings are subjective and will change, the latest Surgery Partners (SGRY) rating was a reiterated with a price target of $0.00 to $43.00. The current price Surgery Partners (SGRY) is trading at is $24.71, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.